Praktikertjänst-backed Aprea Therapeutics has filed for a $68.3m initial public offering that will fund the clinical progress of its cancer drug candidates.
Aprea Therapeutics, a US-based cancer drug developer backed by healthcare provider Praktikertjänst, has filed to raise up to $68.3m in an initial public offering on the Nasdaq Global Select Market.
Founded in Sweden in 2003, Aprea is working on cancer treatments intended to reactivate the mutant p53 tumour suppressor protein, which helps prevent the formation of tumours.
The company’s lead asset, APR-246, is a late-stage candidate for haematologic malignancies, including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) –…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
